View Item 

Show simple item record

Editorial: safety and tolerability of rifaximin for IBS – more information is required; authors' reply
dc.contributor.authorSchoenfeld, P.en_US
dc.contributor.authorPimentel, M.en_US
dc.date.accessioned2014-07-03T14:41:36Z
dc.date.availableWITHHELD_13_MONTHSen_US
dc.date.available2014-07-03T14:41:36Z
dc.date.issued2014-07en_US
dc.identifier.citationSchoenfeld, P.; Pimentel, M. (2014). "Editorial: safety and tolerability of rifaximin for IBS – more information is required; authors' reply." Alimentary Pharmacology & Therapeutics (2): 209-209.en_US
dc.identifier.issn0269-2813en_US
dc.identifier.issn1365-2036en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/107564
dc.publisherWiley Periodicals, Inc.en_US
dc.titleEditorial: safety and tolerability of rifaximin for IBS – more information is required; authors' replyen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/107564/1/apt12837.pdf
dc.identifier.doi10.1111/apt.12837en_US
dc.identifier.sourceAlimentary Pharmacology & Therapeuticsen_US
dc.identifier.citedreferencePimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22 – 32.en_US
dc.identifier.citedreferenceMenees SB, Mannerratanaporn M, Kim HM, et al. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta‐analysis. Am J Gastroenterol 2012; 107: 28 – 35.en_US
dc.identifier.citedreferenceBrandt L, Chey WD, Foxx‐Orenstein A, et al. An evidence‐based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104 ( Suppl. 1 ): S1 – 35.en_US
dc.identifier.citedreferenceCai S‐T, Yang Y‐S. Editorial: safety and tolerability of rifaximin for IBS – more information is required. Aliment Pharmacol Ther 2014; 40: 208.en_US
dc.identifier.citedreferenceSchoenfeld P, Pimente M, Chang L, et al. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double‐blind, placebo‐controlled trials. Aliment Pharmacol Ther 2014; 39: 1161 – 8.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
apt12837.pdf
Size:
50.66KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.